v3.10.0.1
Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount $ 91,788 $ 93,595
Finite-lived intangible assets, accumulated amortization [1] (60,743) (57,033)
Finite-lived intangible assets, less accumulated amortization 31,045 36,562
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 4,165 12,179
Intangible assets, gross carrying amount [1] 95,954 105,774
Identifiable Intangible Assets, less Accumulated Amortization [1],[2] 35,211 48,741
Brands [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [3] 1,994 6,929
In Process Research and Development [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [3] 2,171 5,249
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [3] 89,430 89,550
Finite-lived intangible assets, accumulated amortization [3] (58,895) (54,785)
Finite-lived intangible assets, less accumulated amortization [3] 30,535 34,765
Brands [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [3] 923 2,134
Finite-lived intangible assets, accumulated amortization [3] (708) (1,152)
Finite-lived intangible assets, less accumulated amortization [3] 215 982
Licensing Agreements And Other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 1,436 1,911
Finite-lived intangible assets, accumulated amortization (1,140) (1,096)
Finite-lived intangible assets, less accumulated amortization $ 296 $ 815
[1] The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to the reclassification of $5.8 billion of intangible assets, net, ($6.3 billion total gross carrying amount) to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).
[2] Amounts may not add due to rounding.
[3] The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held for sale during the fourth quarter of 2018 (see Note 2C), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A), (iii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E), as well as impairments of $2.9 billion of Developed technology rights (see Note 4).